

# Michele Spina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754475/publications.pdf>

Version: 2024-02-01

315  
papers

11,599  
citations

26567

56  
h-index

37111

96  
g-index

323  
all docs

323  
docs citations

323  
times ranked

10793  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 266-272.	0.8	688
2	Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. <i>Journal of Clinical Oncology</i> , 2001, 19, 2638-2646.	0.8	574
3	Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>European Journal of Cancer</i> , 2006, 42, 50-54.	1.3	465
4	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	6.3	444
5	HIV-associated lymphomas and gamma-herpesviruses. <i>Blood</i> , 2009, 113, 1213-1224.	0.6	317
6	Clinical Features and Outcome of Primary Effusion Lymphoma in HIV-Infected Patients: A Single-Institution Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3948-3954.	0.8	251
7	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.	1.7	216
8	Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. <i>Blood</i> , 2005, 105, 1891-1897.	0.6	195
9	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 91, 155-163.	2.0	181
10	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 730-737.	5.1	164
11	Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. <i>Blood</i> , 2002, 100, 1984-1988.	0.6	156
12	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	0.6	156
13	High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4423-4427.	0.8	144
14	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. <i>Blood</i> , 2008, 111, 5142-5151.	0.6	142
15	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015, 56, 921-926.	0.6	139
16	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , 2007, 96, 864-867.	2.9	135
17	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. <i>Blood</i> , 2006, 107, 3832-3840.	0.6	133
18	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133

#	ARTICLE	IF	CITATIONS
19	Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. <i>British Journal of Cancer</i> , 2004, 90, 353-358.	2.9	130
20	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. <i>Blood</i> , 2009, 114, 1306-1313.	0.6	130
21	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
22	Relevance of intraocular involvement in the management of primary central nervous system lymphomas. <i>Annals of Oncology</i> , 2002, 13, 531-538.	0.6	120
23	Lung carcinoma in 36 patients with human immunodeficiency virus infection. , 2000, 88, 563-569.		119
24	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	1.9	114
25	First quantification of alpha $\beta$ Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. <i>Xenotransplantation</i> , 2013, 20, 252-261.	1.6	113
26	Non-Hodgkin's lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. <i>International Journal of Cancer</i> , 2004, 110, 380-385.	2.3	107
27	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
28	Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 291-299.	0.8	99
29	Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1675-1688.	1.0	96
30	Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO project (vitalitate exornatum succedaneum aorticum labore) <i>Tj ETQq0 0 0 rgBT 10verlock 10 Tf 50 29</i>		
31	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
32	Burkitt's lymphoma in adults with and without human immunodeficiency virus infection. <i>Cancer</i> , 1998, 82, 766-774.	2.0	87
33	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85
34	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
35	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.5	83
36	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	0.9	82

#	ARTICLE	IF	CITATIONS
37	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 958-966.	0.6	81
38	The influence of heart valve leaflet matrix characteristics on the interaction between human mesenchymal stem cells and decellularized scaffolds. <i>Biomaterials</i> , 2009, 30, 4104-4116.	5.7	79
39	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	2.2	78
40	HIV-associated Hodgkin lymphoma. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 3-10.	1.5	77
41	Improvement of Systemic Human Immunodeficiency Virus-Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2003, 37, 1556-1564.	2.9	76
42	Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. <i>British Journal of Haematology</i> , 2007, 136, 301-304.	1.2	76
43	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
44	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
45	High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. <i>Haematologica</i> , 2004, 89, 1100-8.	1.7	71
46	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255.	1.2	70
47	Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase. <i>Journal of Lipid Research</i> , 2011, 52, 897-907.	2.0	70
48	Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients. <i>Journal of Clinical Oncology</i> , 1996, 14, 2217-2223.	0.8	69
49	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
50	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
51	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
52	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
53	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
54	gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. <i>International Journal of Cancer</i> , 1995, 63, 621-626.	2.3	61

#	ARTICLE	IF	CITATIONS
55	Pegylated interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2009, 145, 255-257.	1.2	60
56	Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. <i>Annals of Oncology</i> , 2006, 17, 713-718.	0.6	59
57	Alpha-Gal detectors in xenotransplantation research: a word of caution. <i>Xenotransplantation</i> , 2012, 19, 215-220.	1.6	59
58	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , 2007, 136, 685-698.	1.2	57
59	Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. <i>European Journal of Cancer</i> , 2001, 37, 1306-1315.	1.3	56
60	Therapeutic approaches to AIDS-related malignancies. <i>Oncogene</i> , 2003, 22, 6646-6659.	2.6	56
61	Outcome in Patients with Non-Hodgkin Lymphoma and With or Without Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2004, 38, 142-144.	2.9	56
62	Effect of hydroxypropyl $\beta$ -cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 32, 115-122.	1.9	55
63	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
64	Hodgkin's disease in 92 patients with HIV infection: The Italian experience. <i>Annals of Oncology</i> , 1992, 3, S69-S72.	0.6	53
65	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
66	Fine Structure of Glycosaminoglycans from Fresh and Decellularized Porcine Cardiac Valves and Pericardium. <i>Biochemistry Research International</i> , 2012, 2012, 1-10.	1.5	51
67	Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. <i>Blood</i> , 2015, 126, 1394-1397.	0.6	50
68	Food groups and risk of non-Hodgkin lymphoma: A multicenter, case-control study in Italy. <i>International Journal of Cancer</i> , 2006, 118, 2871-2876.	2.3	49
69	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM</sc>PET) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
70	Peripheral T cell lymphoma, not otherwise specified (PTCL<math>\text{NOS}</math>). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
71	Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV<math>\text{infected}</math> versus HIV<math>\text{uninfected}</math> Patients with Relapsed or Refractory Lymphoma. <i>Clinical Infectious Diseases</i> , 2010, 50, 1672-1679.	2.9	45
72	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45

#	ARTICLE	IF	CITATIONS
73	A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. <i>Modern Pathology</i> , 2006, 19, 299-306.	2.9	44
74	Comparative evaluation of flavonoid content in assessing quality of wild and cultivated vegetables for human consumption. <i>Journal of the Science of Food and Agriculture</i> , 2008, 88, 294-304.	1.7	44
75	Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 523-531.	0.6	44
76	Physiological Performance of a Detergent Decellularized Heart Valve Implanted for 15 Months in Vietnamese Pigs: Surgical Procedure, Follow-up, and Explant Inspection. <i>Artificial Organs</i> , 2012, 36, E138-50.	1.0	44
77	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43
78	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
79	A new prognostic score for AIDS-related lymphomas in the rituximab-era. <i>Haematologica</i> , 2014, 99, 1731-1737.	1.7	42
80	Biosensor-Based Screening Method for the Detection of Aflatoxins B <sub>1</sub> and G <sub>1</sub> . <i>Analytical Chemistry</i> , 2008, 80, 9250-9256.	3.2	41
81	Hodgkin's Disease in Patients with HIV Infection. <i>Advances in Hematology</i> , 2011, 2011, 1-7.	0.6	41
82	Cancer-related fatigue in the elderly. <i>Supportive Care in Cancer</i> , 2013, 21, 2899-2911.	1.0	40
83	Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. <i>Journal of Clinical Oncology</i> , 1996, 77, 2127-2131.		39
84	Mechanism of inhibition of wt dihydrofolate reductase from <i>E. coli</i> by tea epigallocatechin gallate. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 72, 240-251.	1.5	38
85	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.5	38
86	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. <i>Infectious Agents and Cancer</i> , 2016, 11, 27.	1.2	38
87	Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1992, 3, 843-847.	0.6	37
88	Human Immunodeficiency Virus Seroprevalence and Condom Use Among Female Sex Workers in Italy. <i>Sexually Transmitted Diseases</i> , 1998, 25, 451-454.	0.8	34
89	Characterization of Immunologic and Virological Parameters in HIV-infected Patients with Primary Effusion Lymphoma during Antineoplastic Therapy and Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 40, 1022-1027.	2.9	34
90	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34

#	ARTICLE	IF	CITATIONS
91	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC) "Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. <i>European Journal of Cancer</i> , 2017, 81, 45-55.	1.3	33
92	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. <i>Cancer Research</i> , 2005, 65, 587-95.	0.4	33
93	AIDS-related tumors: integrating antiviral and anticancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 299-315.	2.0	32
94	Wheat sprout extract induces changes on 20S proteasomes functionality. <i>Biochimie</i> , 2008, 90, 790-801.	1.3	32
95	Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3854-3863.	0.8	32
96	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 212-218.	0.7	32
97	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
98	Neoplastic complications of HIV infection. <i>Annals of Oncology</i> , 1999, 10, 1271-1286.	0.6	31
99	The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2008, 122, 1624-1629.	2.3	31
100	Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. <i>Journal of Medical Virology</i> , 2009, 81, 888-896.	2.5	31
101	Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 1495-1501.	2.0	30
102	Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. <i>Human Reproduction</i> , 2014, 29, 525-533.	0.4	30
103	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	0.6	30
104	Hodgkin's disease in HIV. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 843-858.	0.9	29
105	Patients With HIV With Burkitt's Lymphoma Have a Worse Outcome Than Those With Diffuse Large-Cell Lymphoma Also in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2005, 23, 8132-8133.	0.8	29
106	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF- $\kappa$ B pathway as a target for new therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2008, 49, 2048-2058.	0.6	29
107	Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome. <i>American Journal of Hematology</i> , 2011, 86, 170-179.	2.0	29
108	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28

#	ARTICLE	IF	CITATIONS
109	Human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 92, 200-206.	2.0	27
110	Comprehensive Geriatric Evaluation in Elderly Patients With Lymphoma: Feasibility of a Patient-Tailored Treatment Plan. <i>Journal of Clinical Oncology</i> , 2003, 21, 754-754.	0.8	27
111	Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome. <i>American Journal of Hematology</i> , 2013, 88, 161-162.	2.0	27
112	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	1.7	27
113	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	1.8	27
114	Smoking and non-Hodgkin lymphoma: Case-control study in Italy. <i>International Journal of Cancer</i> , 2005, 115, 606-610.	2.3	26
115	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. <i>Haematologica</i> , 2008, 93, 1178-1185.	1.7	26
116	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	0.6	26
117	Clinical significance of positive direct antiglobulin test in patients with HIV infection. <i>Infection</i> , 1994, 22, 92-95.	2.3	25
118	Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. <i>Aids</i> , 2003, 17, 137-138.	1.0	25
119	Pomegranate fruit components modulate human thrombin. <i>Farmacoterapia</i> , 2009, 80, 301-305.	1.1	25
120	Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial. <i>Diabetes and Metabolism</i> , 2011, 37, 124-130.	1.4	25
121	Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. <i>Annals of Oncology</i> , 1998, 9, 923.	0.6	24
122	Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. <i>Annals of Oncology</i> , 2002, 13, 1341-1346.	0.6	24
123	Decellularized aortic conduits: could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts. <i>Heart and Vessels</i> , 2016, 31, 1862-1873.	0.5	24
124	Dietary Folate, Alcohol Consumption, and Risk of Non-Hodgkin Lymphoma. <i>Nutrition and Cancer</i> , 2007, 57, 146-150.	0.9	23
125	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. <i>Tissue Antigens</i> , 2010, 75, 127-135.	1.0	22
126	Tissue-Specific Expression and Regulatory Networks of Pig MicroRNAs. <i>PLoS ONE</i> , 2014, 9, e89755.	1.1	22



#	ARTICLE	IF	CITATIONS
127	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
128	Lung cancer in 19 patients with HIV infection. <i>Annals of Oncology</i> , 1993, 4, 85-86.	0.6	21
129	Impact of Concomitant Antiblasic Chemotherapy and Highly Active Antiretroviral Therapy on Human Immunodeficiency Virus (HIV) Viremia and Genotyping in HIV-infected Patients with Non-Hodgkin Lymphoma. <i>Clinical Infectious Diseases</i> , 2003, 37, 820-827.	2.9	21
130	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017, 102, e203-e206.	1.7	21
131	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
132	Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism. <i>Clinical Nutrition</i> , 2022, 41, 698-708.	2.3	21
133	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. <i>Digestive and Liver Disease</i> , 2007, 39, S65-S71.	0.4	20
134	IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007, 40, 1019-1025.	1.3	20
135	Clinical Evaluation of 451 Patients with HIV Related Non-Hodgkin's Lymphoma: Experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). <i>Leukemia and Lymphoma</i> , 1995, 20, 91-96.	0.6	19
136	Rituximab for HIV-associated lymphoma: weighing the benefits and risks. <i>Current Opinion in Oncology</i> , 2005, 17, 462-465.	1.1	19
137	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	1.8	19
138	Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection. <i>Current HIV Research</i> , 2010, 8, 218-222.	0.2	19
139	The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. <i>Cancer Epidemiology</i> , 2010, 34, 257-261.	0.8	19
140	The role of diet in gastric cancer: still an open question. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1640.	3.0	19
141	Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. <i>Expert Review of Hematology</i> , 2015, 8, 217-223.	1.0	19
142	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
143	Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 353-364.	1.4	18
144	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e1-e9.	0.2	17

#	ARTICLE	IF	CITATIONS
145	Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. <i>Annals of Oncology</i> , 1999, 10, S87-S90.	0.6	16
146	Hodgkin Lymphoma in HIV Positive Patients. <i>Current HIV Research</i> , 2010, 8, 141-146.	0.2	16
147	Mutations of <i>CD79A</i> , <i>CD79B</i> and <i>EZH2</i> genes in immunodeficiency-related non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2011, 152, 777-780.	1.2	16
148	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016, 140, S177.	0.8	16
149	Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer</i> , 1995, 76, 535-536.	2.0	15
150	Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 252-255.	1.2	15
151	Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15
152	LONG-TERM SURVIVAL OF PATIENTS WITH HIV-RELATED SYSTEMIC NON-HODGKIN'S LYMPHOMAS. , 1996, 14, 7-15.		14
153	HIV-related non-Hodgkin's lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management. <i>Annals of Oncology</i> , 2004, 15, 993-995.	0.6	14
154	Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. <i>Clinical and Experimental Immunology</i> , 2007, 148, 402-409.	1.1	14
155	IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 4080-4091.	3.2	14
156	Cardiomyocytes In Vitro Adhesion Is Actively Influenced by Biomimetic Synthetic Peptides for Cardiac Tissue Engineering. <i>Tissue Engineering - Part A</i> , 2012, 18, 725-736.	1.6	14
157	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. <i>Hematological Oncology</i> , 2013, 31, 22-28.	0.8	14
158	Hodgkin's disease in HIV-infected individuals. <i>Current Opinion in Oncology</i> , 1999, 11, 522.	1.1	14
159	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, e7-e7.	0.8	13
160	Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. <i>Aids</i> , 2013, 27, 1033-1035.	1.0	13
161	Graphene Oxide increases mammalian spermatozoa fertilizing ability by extracting cholesterol from their membranes and promoting capacitation. <i>Scientific Reports</i> , 2019, 9, 8155.	1.6	13
162	The Vietnamese pig as a translational animal model to evaluate tissue engineered heart valves: promising early experience. <i>International Journal of Artificial Organs</i> , 2017, 40, 142-149.	0.7	13

#	ARTICLE	IF	CITATIONS
163	Cancer in the elderly: The caregiversâ€™ perception of senior patientsâ€™ informational needs. Archives of Gerontology and Geriatrics, 2009, 49, e121-e125.	1.4	12
164	Natural Scaffolds for Regenerative Medicine: Direct Determination of Detergents Entrapped in Decellularized Heart Valves. BioMed Research International, 2017, 2017, 1-9.	0.9	12
165	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	0.8	12
166	MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. International Journal of Biological Markers, 2007, 22, 307-311.	0.7	12
167	The changing hydrodynamic performance of the decellularized intact porcine aortic root: considerations on in-vitro testing. Journal of Heart Valve Disease, 2010, 19, 485-91.	0.5	12
168	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances, 2022, 6, 2035-2044.	2.5	12
169	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	1.7	11
170	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica, 2017, 102, 1931-1935.	1.7	11
171	Native Bovine and Porcine Pericardium Respond to Load With Additive Recruitment of Collagen Fibers. Artificial Organs, 2018, 42, 540-548.	1.0	11
172	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. Haematologica, 2020, 105, e72-e75.	1.7	11
173	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. Tumori, 2021, 107, 91-94.	0.6	11
174	Human immunodeficiency virus as a risk factor in miscellaneous cancers. Current Opinion in Oncology, 1992, 4, 907-910.	1.1	10
175	Prognostic Factors in Human Herpesvirus 8-Related Lymphoproliferative Disorders Associated With HIV Infection. Journal of Clinical Oncology, 2006, 24, 209-209.	0.8	10
176	Can the caregiver replace his/her elderly cancer patient in the physicianâ€™patient line of communication?. Supportive Care in Cancer, 2008, 16, 1157-1162.	1.0	10
177	KIR/HLA Combination Associated with the Risk of Complications in Celiac Disease. International Journal of Biological Markers, 2011, 26, 221-228.	0.7	10
178	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 71-76.	0.6	10
179	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. Blood, 2019, 134, 398-398.	0.6	10
180	Two types of fatigue in cancer patients. British Journal of Cancer, 2012, 106, 424-424.	2.9	9

#	ARTICLE	IF	CITATIONS
181	Is It Better to Transfer Long-Term Cancer Survivors to General Practitioners or Develop Clinics for Long-Term Survivors Within the Cancer Centers?. <i>Journal of Clinical Oncology</i> , 2014, 32, 257-257.	0.8	9
182	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	1.1	9
183	Low-dose radiotherapy in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 472-479.	0.8	9
184	Other cancers in HIV-infected patients. <i>Current Opinion in Oncology</i> , 1994, 6, 508-512.	1.1	8
185	High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. <i>Annals of Oncology</i> , 2003, 14, 655-656.	0.6	8
186	Regression of Low-Grade Non-Hodgkin's Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection. <i>Journal of Clinical Oncology</i> , 2005, 23, 4470-4471.	0.8	8
187	Family History of Hemolymphopoietic and Other Cancers and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 245-250.	1.1	8
188	Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. <i>Annals of Oncology</i> , 2006, 17, 1176-1177.	0.6	8
189	Tissue-Engineered Heart Valves: Intra-operative Protocol. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 660-661.	1.1	8
190	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
191	Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. <i>Aids</i> , 2000, 14, 1457-1458.	1.0	8
192	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
193	Cetuximab/Targeted Chemotherapy in an HIV-Positive Patient with Metastatic Colorectal Cancer in the HAART Era: a Case Report. <i>Journal of Chemotherapy</i> , 2007, 19, 343-346.	0.7	7
194	FOLFOX-4 Regimen with Concomitant Highly Active Antiretroviral Therapy in Metastatic Colorectal Cancer HIV-Infected Patients: A Report of Five Cases and Review of the Literature. <i>Cancer Investigation</i> , 2008, 26, 610-614.	0.6	7
195	New treatment strategies for HIV-positive cancer patients undergoing antineoplastic chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2391-2403.	0.9	7
196	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
197	Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. <i>Bone Marrow Transplantation</i> , 2018, 53, 228-230.	1.3	7
198	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	0.8	7

#	ARTICLE	IF	CITATIONS
199	A doseâ€dense shortâ€term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with highâ€risk Burkitt lymphoma or highâ€grade Bâ€cell lymphoma: safety and efficacy results of the â€œCARMENâ€ phase II trial. <i>British Journal of Haematology</i> , 2021, 192, 119-128.	1.2	7
200	Immunodeficiency-associated Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 547-559.	1.0	7
201	Hodgkinâ€™s Disease: Clinical Presentation and Treatment. <i>Cancer Treatment and Research</i> , 2001, 104, 247-265.	0.2	7
202	Massive myocardial infiltration by HIV-related non-Hodgkin lymphoma. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 836-838.	0.6	7
203	Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2010, 116, 1761-1761.	0.6	7
204	Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer â€” a phase II trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 45-49.	2.0	6
205	Therapeutic options for HIV-associated lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2471-2481.	0.9	6
206	Autograft HIV-DNA Load Predicts HIV-1 Peripheral Reservoir After Stem Cell Transplantation for AIDS-Related Lymphoma Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 150-159.	0.5	6
207	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
208	Condom use and high-risk sexual practices of female prostitutes in Italy. <i>Aids</i> , 1992, 6, 601.	1.0	5
209	Peroxynitrite-mediated oxidation of the C85S/C152E mutant of dihydrofolate reductase from <i>Escherichia coli</i> : functional and structural effects. <i>Archives of Biochemistry and Biophysics</i> , 2005, 434, 221-231.	1.4	5
210	Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia. <i>Digestive and Liver Disease</i> , 2007, 39, S102-S106.	0.4	5
211	Human immunodeficiency virusâ€associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. <i>Human Pathology</i> , 2009, 40, 1045-1049.	1.1	5
212	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020, 99, 283-291.	0.8	5
213	Skin carcinoma in 2 patients with HIV infection. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1184.	0.9	4
214	Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 157-162.	2.0	4
215	Influence of Dietary Feeding of Low Monomer Content Grape Seed Extract on Vitellogenin Production and Cholesterol Levels in Goldfish, <i>Carassius auratus</i> . <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 1860-1866.	2.4	4
216	Biocompatibility Issues of Next Generation Decellularized Bioprosthetic Devices. <i>Conference Papers in Science</i> , 2014, 2014, 1-6.	0.3	4

#	ARTICLE	IF	CITATIONS
217	Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study. <i>Blood</i> , 2018, 132, 5294-5294.	0.6	4
218	Hodgkin's Disease and HIV Infection (HD-HIV): Prognostic Factors In 596 Patients (pts) within the European Group for the Study of HIV and Tumours (GECAT). <i>Blood</i> , 2010, 116, 3883-3883.	0.6	4
219	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 903-903.	0.6	4
220	Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program. <i>Blood</i> , 2016, 128, 2985-2985.	0.6	4
221	Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 4528-4528.	0.8	4
222	Final results of a multicentre phase II trial of high-dose methotrexate (HD-MTX), cytarabine, thiotepa, and idarubicin (MATILDE regimen) followed by whole-brain irradiation (WBRT) for primary CNS lymphomas (PCNSL). <i>Journal of Clinical Oncology</i> , 2005, 23, 1530-1530.	0.8	4
223	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. <i>International Journal of Oncology</i> , 2005, 26, 945.	1.4	3
224	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2006, 17, 533.	0.6	3
225	Protein Expression Profile of Celiac Disease Patient with Aberrant T Cell by Two-dimensional Difference Gel Electrophoresis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 429-440.	1.8	3
226	PET-adapted salvage therapy in Hodgkin's lymphoma. <i>Lancet Oncology</i> , The, 2015, 16, 239-240.	5.1	3
227	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 378-384.	0.6	3
228	HCV and HIV-Related Non-Hodgkin's Lymphoma. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 80.	0.3	3
229	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 850-850.	0.6	3
230	Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study. <i>Blood</i> , 2015, 126, 1541-1541.	0.6	3
231	Virological efficacy in HIV-infected patients affected by non-hodgkin lymphoma, treated with antineoplastic chemotherapy and highly active antiretroviral therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 49-53.	1.5	2
232	Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. <i>Aids</i> , 2004, 18, 1859-1861.	1.0	2
233	Cancer Prevention and Early Diagnosis in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 628-629.	0.9	2
234	Is high-dose chemotherapy with peripheral stem cell rescue a suitable option for elderly patients affected by aggressive non-Hodgkin's lymphoma?. <i>Annals of Oncology</i> , 2005, 16, 837-838.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2677-2680.	0.6	2
236	An IELSG International Survey of Primary Effusion Lymphoma (PEL).. <i>Blood</i> , 2004, 104, 3265-3265.	0.6	2
237	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. <i>Blood</i> , 2010, 116, 2821-2821.	0.6	2
238	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFLO9). <i>Blood</i> , 2013, 122, 3049-3049.	0.6	2
239	Early Consolidation with High Dose Therapy and Autologous Stem Cell Transplantation in HIV-Associated Non Hodgkin Lymphoma at High Risk (aa-IPi 2-3). Mature Results of a Multicenter Prospective Phase II Trial. <i>Blood</i> , 2014, 124, 2528-2528.	0.6	2
240	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	0.6	2
241	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016, 128, 472-472.	0.6	2
242	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7538-7538.	0.8	2
243	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3049-3049.	0.6	2
244	Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?. <i>Annals of Oncology</i> , 2004, 15, 1298.	0.6	1
245	Is Long-Term Fatigue in Patients With Cancer an Infrequent Symptom?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4175-4175.	0.8	1
246	A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). <i>Annals of Oncology</i> , 2016, 27, vi316.	0.6	1
247	Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-Up Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S139-S140.	0.4	1
248	Reference values for the EORTC QLQâ€œ30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , 2021, 106, 697-707.	1.1	1
249	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.	0.8	1
250	Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (>70 Years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 2440-2440.	0.6	1
251	A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes. <i>Blood</i> , 2012, 120, 3682-3682.	0.6	1
252	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2015, 33, TPS8600-TPS8600.	0.8	1
254	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).. Journal of Clinical Oncology, 2018, 36, 7548-7548.	0.8	1
255	Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1412-1418.	0.9	1
256	R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL). Journal of Clinical Oncology, 2007, 25, 8036-8036.	0.8	1
257	Peripheral Blood Stem Cell Mobilization In Hiv Positive Patients with Lymphoma Candidates to Autologous Transplantation: Predictive Factors Analysis for Failure or Suboptimal Stem Cell Collection. Blood, 2010, 116, 2250-2250.	0.6	1
258	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). Blood, 2015, 126, 3934-3934.	0.6	1
259	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. Blood, 2015, 126, 1547-1547.	0.6	1
260	HIV-Associated Hodgkin Lymphoma. , 2016, , 119-132.		1
261	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood, 2016, 128, 921-921.	0.6	1
262	Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial. Blood, 2016, 128, 474-474.	0.6	1
263	CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2017, 35, e14039-e14039.	0.8	1
264	In vitro Proteolysis of the Red Cell Membrane in Patients with HIV Infection. Pathobiology, 1995, 63, 42-47.	1.9	0
265	Prostitution: to decriminalise or to legalise. Lancet, The, 1996, 348, 962.	6.3	0
266	HIV-1 infection and prostitutes. Lancet, The, 1998, 351, 1214.	6.3	0
267	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
268	High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 2444-2446.	0.6	0
269	OC3.05.4 RELATIONSHIP BETWEEN GALECTIN-10 EXPRESSION AND SEVERITY OF CELIAC DISEASE ABOLISHED IN THE PRESENCE OF T CELL CLONAL EXPANSION. Digestive and Liver Disease, 2008, 40, S49-S50.	0.4	0
270	PA.40 IDENTIFICATION OF A NEW HLA-A*680102 VARIANT, ASSOCIATED WITH ANCESTRAL HAPLOTYPIC B8-DR3 FROM TWO ITALIAN PATIENTS FROM FRIULI WITH CELIAC DISEASE. Digestive and Liver Disease, 2008, 40, S90.	0.4	0



#	ARTICLE	IF	CITATIONS
271	P16 Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (> 70 years) with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): final results and long term follow-up. Critical Reviews in Oncology/Hematology, 2009, 72, S24-S25.	2.0	0
272	AIDS-Related Lymphoma. , 2013, , 257-266.		0
273	Lymphoma in the immunosuppressed. , 0, , 273-285.		0
274	PO-0666: Comparing the efficacy of low-dose radiotherapy in patients with aggressive and indolent lymphomas. Radiotherapy and Oncology, 2016, 119, S311.	0.3	0
275	PO-0665: Compliance with ILROG guidelines in the treatment of extranodal lymphomas; an internal plans review. Radiotherapy and Oncology, 2016, 119, S310.	0.3	0
276	REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY <sc>H</sc>ODGKIN'S LYMPHOMA. Hematological Oncology, 2017, 35, 170-171.	0.8	0
277	LONG-TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT). Hematological Oncology, 2019, 37, 256-257.	0.8	0
278	Non-Hodgkin's lymphoma (NHL) in elderly patients (pts): Patient-tailored treatment according to a comprehensive geriatric evaluation. Journal of Clinical Oncology, 2004, 22, 6678-6678.	0.8	0
279	Stanford V regimen in 59 patients (pts) with HD and HIV Infection (HD-HIV): A very effective approach in the long-term analysis. Journal of Clinical Oncology, 2006, 24, 7583-7583.	0.8	0
280	Reactivity of an Anti NS3-HCV-Induced Autoantibody in HCV-Positive Gastric Tissue by 2D Gel Immunoblot.. Blood, 2006, 108, 4658-4658.	0.6	0
281	Proteomic Profile of Human Gut Biopsies from Celiac Patients with and without Severe Complications.. Blood, 2006, 108, 3899-3899.	0.6	0
282	Use of biological drugs in elderly cancer patients: A sustainable reality? A mono-institutional experience. Journal of Clinical Oncology, 2007, 25, 19665-19665.	0.8	0
283	Ca-15.3 antigen as predictor of response to EGFR inhibitors in patients with bronchiolo-alveolar carcinoma. Journal of Clinical Oncology, 2007, 25, 18151-18151.	0.8	0
284	The impact of HCV co-infection on the outcome and the clinical features of HIV-related non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology, 2008, 26, 19504-19504.	0.8	0
285	Maintenance immunotherapy after autologous bone marrow transplantation (ABMT) in relapsed follicular (R-FL) and mantle cell (R-MC) lymphomas (NHL). A monoinstitutional experience. Journal of Clinical Oncology, 2008, 26, 18012-18012.	0.8	0
286	Use of targeted agents in elderly cancer patients (ECP) according to the Comprehensive Geriatric Assessment (CGA). Journal of Clinical Oncology, 2008, 26, 20619-20619.	0.8	0
287	FOLFOX4 and concomitant highly active antiretroviral therapy (HAART) in metastatic colorectal cancer (M-CRC) HIV-positive patients (pts): A GICAT experience. Journal of Clinical Oncology, 2008, 26, 15046-15046.	0.8	0
288	Extranodal lymphomas in patients with HIV infection. , 2008, , 289-298.		0

#	ARTICLE	IF	CITATIONS
289	Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (IGE) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients. Journal of Clinical Oncology, 2009, 27, 8568-8568.	0.8	0
290	Mortality for non-AIDS-defining cancers among people with AIDS.. Journal of Clinical Oncology, 2010, 28, 1590-1590.	0.8	0
291	The Management of HIV-Hodgkin Lymphoma. , 2011, , 249-258.		0
292	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2651-2651.	0.6	0
293	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2636-2636.	0.6	0
294	ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era. Blood, 2012, 120, 1564-1564.	0.6	0
295	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). Blood, 2012, 120, 1615-1615.	0.6	0
296	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ®, ¢) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). Blood, 2012, 120, 3644-3644.	0.6	0
297	Hodgkin Lymphoma in Patients with HIV Infection. , 2013, , 1-8.		0
298	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). Blood, 2013, 122, 3055-3055.	0.6	0
299	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. Blood, 2013, 122, 5088-5088.	0.6	0
300	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. Blood, 2013, 122, 1782-1782.	0.6	0
301	Hodgkin Lymphoma in Patients with HIV Infection. , 2014, , 235-243.		0
302	HIV-Associated Lymphomas. , 2014, , 225-240.		0
303	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. Journal of Clinical Oncology, 2014, 32, 9641-9641.	0.8	0
304	Multicenter Study with Mbvd Regimen in Elderly or Younger Patients with Cardiac Disorders Affected By Hodgkinâ€™s Lymphoma. a Phase II Study on Behalf of the Fondazione Italiana Linfomi (FIL). Blood, 2014, 124, 1732-1732.	0.6	0
305	Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL. Blood, 2014, 124, 4429-4429.	0.6	0
306	Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study. Blood, 2014, 124, 5979-5979.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Diagnosis, Prophylaxis and Treatment of Central Nervous System Involvement by Non-Hodgkin Lymphoma in HIV-Infected Patients. , 2016, , 215-221.		0
308	Cancer survivorship: Is there a role for cancer survivor clinics?. Journal of Clinical Oncology, 2016, 34, e272-e272.	0.8	0
309	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 4161-4161.	0.6	0
310	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 3007-3007.	0.6	0
311	Hodgkin Lymphoma in Patients with HIV Infection. , 2018, , 1008-1015.		0
312	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Blood, 2018, 132, 2890-2890.	0.6	0
313	Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years. Blood, 2018, 132, 1688-1688.	0.6	0
314	The Management of HIV-Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 335-347.	0.2	0
315	High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma. Journal of Clinical Oncology, 2004, 22, 6506-6506.	0.8	0